World Alzheimer’s Day: Sant Pau Focuses on Individuals with Down Syndrome

On World Alzheimer’s Day, the aim is to raise awareness about this incurable neurodegenerative disease that primarily affects elderly individuals. However, this year, Hospital de Sant Pau has shifted its attention to a particularly vulnerable group: individuals with Down syndrome. Alzheimer’s is characterized by cognitive decline and behavioral disturbances, with recent memory loss being one … Read more

Synaptic Tau Oligomers in Alzheimer’s Disease – A Possible Culprit in the Spread of Tau Pathology throughout the Brain

Synaptic Tau Oligomers in Alzheimer's Disease - A Possible Culprit in the Spread of Tau Pathology throughout the Brain2

Synaptic Tau Oligomers in Alzheimer’s Disease – A Possible Culprit in the Spread of Tau Pathology throughout the Brain   Alzheimer’s disease is considered one of the most common causes of dementia in older individuals. Among the neuropathological features of Alzheimer’s disease (AD), the synaptic loss is the primary correlate of cognitive decline, and the … Read more

Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer’s disease in adults with Down syndrome

Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer's disease in adults with Down syndrome

Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer’s disease in adults with Down syndrome Individuals with Down syndrome are at a high risk of developing the clinical symptoms of Alzheimer’s disease in old age due to the triplicating of chromosome 21. However, the clinical diagnosis of this disease is challenging, mainly due … Read more

GFAP in plasma and CSF in Down syndrome and Alzheimer’s disease

gfap - Sant Pau Memory Unit - Montoliu-Gaia - Alcolea

Alzheimer’s Disease, Down Syndrome and GFAP People with Down syndrome are at higher risk of developing Alzheimer’s disease than the general population. In fact, by the age of 70, more than 95% of people with Down syndrome will develop Alzheimer’s disease, which is the leading cause of death in this population. This strong association is … Read more

Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist

blood-based biomarkers in neurodegenerative diseases

Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia, are a growing health concern worldwide, and their diagnosis and management are still challenging. However, recent advances in blood-based biomarkers offer new opportunities for clinical evaluation and monitoring of these diseases. In this review article, entitled “Blood Biomarkers in Neurodegenerative Diseases: Implications for the … Read more

Amyloid precursor protein βCTF accumulates in synapses in sporadic and genetic forms of Alzheimer’s disease

Amyloid precursor protein βCTF accumulates in synapses in sporadic and genetic forms of Alzheimer’s disease

Amyloid precursor protein βCTF accumulates in synapses in sporadic and genetic forms of Alzheimer’s disease The main pathological features observed in a brain with Alzheimer’s disease (AD) are the accumulation of β-amyloid (Aβ) peptides in the form of plaques and the aggregation of phosphorylated tau protein. Amyloid precursor protein (APP) can be processed via the amyloidogenic … Read more